Fundraising Fox

Gilgamesh Pharmaceuticals

YC S20 ↗

New York City, US · Founded 2019 · Delaware corporation · 15 employees · 10 known investors

gilgameshpharmaceutical.com ↗

Gilgamesh Pharmaceutical develops novel chemical entities for psychiatric disorders using medicinal chemistry and AI-powered translational platforms to design rapid-acting therapies targeting neurobiological mechanisms rather than symptom management. The company's pipeline spans depression, anxiety, addiction, and schizophrenia, with programs validated by AbbVie's acquisition of its first asset and partnerships with Columbia University and the National Institute on Drug Abuse.

AI & Machine LearningBiotechDigital HealthHealthtechTherapeuticsPsychedelicsMental Healthin /gilgamesh-pharmaceuticals/@GilgameshRXycombinator.com ↗

Founders & leadership· Y Combinator alumni (S20)

JSJonathan Sporn
Jonathan SporninFounder
AKAndrew Kruegel
Andrew KruegelinFounder
DSDalibor Sames
Dalibor SamesinFounder
JSJONATHAN SPORN
JONATHAN SPORNinFounder
TK
Thomas Kevin Murphy, Ph.D.Executive Officer
AK
Andrew Kruegel, Ph.D.Executive Officer
JS
Jonathan Sporn, M.D.President and Chief Executive Officer

Investors · 10

Aera VCSingapore · $25K – $5M
Frontera Technology VenturesTexas
Frontier Path VCLondon
James Beshara FundLos Angelesvia James J Beshara · inferred
JLSNew York
Magnetic VenturesBoston · $1M – $6M
NoeticToronto, Ontario
Prime Movers LabJackson · $2M – $30Mvia Gaetano Crupi · board
PsyMed VenturesBerkeley
Y CombinatorSan Francisco · $500K

Reported raises · per SEC filings

Form D private placements
▶$13.8MraisedMay 2022 · 14 investors · Pharmaceuticals
Rule 506(c)
Officers, directors & promoters on the filing
  • Robert BermanDirector
  • Gerard MarekExecutive Officer
  • Phil SkolnickDirector
  • Jonathan SpornExecutive Officer, Director
  • Yoni FalksonExecutive Officer
  • Thomas Kevin MurphyExecutive Officer
  • Andrew KruegelExecutive Officer, Director
  • Gaetano CrupiDirector
  • Laszlo KissExecutive Officer
  • Amy KruseDirector
Offering amount
$50M
Amount sold
$13.8M
Minimum investment
$50K
First sale
May 2022
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$951offeredFeb 2022 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert BermanDirector
  • Phil SkolnickDirector
  • Amy KruseDirector
  • Andrew KruegelExecutive Officer, Director
  • Jonathan SpornExecutive Officer, Director
Offering amount
$951
Minimum investment
$951
First sale
Feb 2022
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$34.7MraisedMay 2021 · 66 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Andrew KruegelExecutive Officer, Director
  • Amy KruseDirector
  • Robert BermanDirector
  • Dalibor SamesDirector
  • Jonathan SpornExecutive Officer, Director
Offering amount
$34.7M
Amount sold
$34.7M
Minimum investment
$10K
Proceeds to insiders
$630K
First sale
Apr 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$735KraisedSep 2020 · 10 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Dalibor SamesDirector
  • Andrew KruegelDirector
  • Jonathan SpornExecutive Officer, Director
Amount sold
$735K
Minimum investment
$10K
First sale
Aug 2020
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$150KraisedJul 2020 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jonathan Sporn, M.D.Executive Officer, Director
  • Andrew Kruegel, Ph.D.Executive Officer
  • Thomas Kevin Murphy, Ph.D.Executive Officer
Offering amount
$150K
Amount sold
$150K
Minimum investment
$150K
First sale
Jul 2020
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.4MraisedJul 2020 · 25 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas Kevin Murphy, Ph.D.Executive Officer
  • Andrew Kruegel, Ph.D.Executive Officer
  • Jonathan Sporn, M.D.Executive Officer, Director
Amount sold
$2.4M
First sale
Apr 2020
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news